By far the two most common prostate diseases are prostatitis and benign hyperplasia (BPH). Prostatitis can be complicated by BPH or accompanied by intermittent exacerbations. Medication is an important part of the overall treatment of prostate disease. In addition, treatment is inadequate due to inadequate therapy, missed medications, and when the condition subsides, disregard for the disease.
Thus, 20-30% of patients are dissatisfied with the treatment, do not feel a reduction in the symptoms of urinary disorders and an improvement in their quality of life. This is probably due to a misjudgment of low urinary tract function in men with BPH and the choice of inappropriate treatment accordingly.
As you know, prostatitis is acute and chronic (CP), bacterial and bacterial.
Prostatitis in%
- acute bacterial prostatitis - 5-10%;
- chronic bacterial prostatitis - 6-10%;
- chronic abacterial prostatitis - 80-90%, including prostatodynia - 20-30%.
The most common is chronic bacterial prostatitis, which should be monitored and prevented in time with exacerbations with and without BPH.
The main drugs used to treat BPH and chronic prostatitis are:
- 5α-reductase inhibitors (finasteride, dutasteride);
- α-blockers (doxazosin, tamsulosin);
- phytotherapy (sabal palm extract);
- antibiotics;
- amino acid complexes;
- animal organ extracts (prostate extract);
- entomotherapy drugs (products of insect origin).
However, in 13-30% of α-blockers, treatment does not occur within 3 months - further treatment with this group of drugs is not recommended.
When prescribing finasteride, the physician should be prepared for the fact that the most significant side effects of the drug: impotence, decreased libido, decreased ejaculate volume may lead to self-withdrawal of the patient.
The treatment of BPH and prostatitis is an important, not completely solved urological problem.
Frequent exacerbation of CP in the absence of surgical indications for the prostate gland forces the physician to use additional methods of medication. Often, the presence of concomitant CP exacerbates the course of BPH, and in 80% of cases, the inflammation is in the prostate with benign hyperplasia.
Modern medicine offers us new opportunities in the treatment of CP and BPH and in the prevention of exacerbations.